Participants 126 158 3
Patients With Metabolic Syndrome
Participants 355 427 4
patients with metabolic syndrome, with and without stable statin therapy
Participants 482 818 5
patients with metabolic syndrome treated with IPE 4 grams/day, IPE 2 grams/day, or placebo in phase 3, randomized, placebo-controlled studies entitled: MARINE [triglyceride (TG) levels ≥500 and ≤2000 mg/dL] and ANCHOR [TG levels ≥200 and <500 mg/dL, despite low-density lipoprotein cholesterol (LDL-C) control with stable stat
Participants 854 923 3
lacebo in patients with metabolic syndrome in MARINE (n=204) and ANCH
